VaxGen Wins Contract for Anthrax Vaccine
- Share via
Vaccine developer VaxGen Inc. said it was awarded an $80.3-million contract from the National Institutes of Health for development of an experimental anthrax vaccine. The three-year contract could pave the way for a significantly larger contract for a national stockpile of anthrax vaccine, the San Diego-based company said.
The company’s shares, which have fallen 31% this year, rose 7 cents to $12.07 on Nasdaq before the contract award was announced.
VaxGen plans to manufacture the protein antigen used in the vaccine in its manufacturing facility in South San Francisco.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
